Evaluate the expected performance of Somnigroup International (SGI) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Get a deeper insight into the potential performance of The AZEK Company (AZEK) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Besides Wall Street's top -and-bottom-line estimates for Texas Roadhouse (TXRH), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.

Get a deeper insight into the potential performance of TransMedics (TMDX) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Get a deeper insight into the potential performance of Wheaton Precious Metals (WPM) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Cleveland-Cliffs (CLF), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.

Beyond analysts' top -and-bottom-line estimates for Monster Beverage (MNST), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.

Evaluate the expected performance of Flex (FLEX) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Besides Wall Street's top -and-bottom-line estimates for Restaurant Brands (QSR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.

Get a deeper insight into the potential performance of American Financial (AFG) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Get a deeper insight into the potential performance of Bumble (BMBL) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Besides Wall Street's top -and-bottom-line estimates for Bentley Systems (BSY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.

Beyond analysts' top -and-bottom-line estimates for Illumina (ILMN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.

Besides Wall Street's top -and-bottom-line estimates for Warner Bros. Discovery (WBD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Royalty Pharma (RPRX), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2025.

Beyond analysts' top -and-bottom-line estimates for Fiverr (FVRR), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.

Amazon.com Inc NASDAQ: AMZN closed out last week just under the $190 mark, following a much-anticipated earnings report that, while beating expectations on both revenue and EPS, came with cautious guidance that initially held shares back from breaking higher.

Rising demand for renewable energy is adding uncertainty to the prospects of the Zacks Oil and Gas Integrated International industry's outlook. XOM, CVX and BP will probably overcome market challenges.

Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.

Following a careful analysis of the Zacks Transportation - Services industry, we advise investors to keep a tab on companies like EXPD, CHRW and MATX.